Molecular and Immunohistochemical assessment of Fibroblast Growth Factor Receptor 3 (FGFR3) gene as a survival time predictor in bladder cancer patients

Samah Mamdouh; Tarek  Aboushousha; Olfat Hammam; Fatma Khorshed; Gehan Safwat; Khaled  Elesaily

doi:10.3889/oamjms.2023.11372

Authors

Samah Mamdouh Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Cairo, Egypt
Tarek Aboushousha Department of Pathology, Theodor Bilharz Research Institute, Cairo, Egypt https://orcid.org/0000-0002-6686-2442
Olfat Hammam Department of Pathology, Theodor Bilharz Research Institute, Cairo, Egypt https://orcid.org/0000-0002-4965-5804
Fatma Khorshed Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Cairo, Egypt https://orcid.org/0000-0003-0642-1239
Gehan Safwat Faculty of Biotechnology, October University for Modern Sciences and Arts, Giza, Egypt
Khaled Elesaily Department of Urology, Theodor Bilharz Research Institute, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2023.11372

Keywords:

Bladder Cancer, FGFR3, Recurrence, Survival time, FISH, IHC

Abstract

BACKGROUND: Mutation signatures contributing to the tumorigenesis of bladder cancer (BC) are complex and heterogeneous, resulting in unpredictable progression, recurrence, and time survival. Clinically, useful prognostic and predictive biomarkers for both disease recurrence and surveillance are therefore needed. Activating fibroblast growth factor receptor 3 (FGFR3) mutations are regarded as early drivers in the molecular pathogenesis of BC.

AIM: The aim of the present study is to evaluate the frequency and distribution pattern of FGFR3 mutation in urine sediments of BC patients in relation to its immunohistochemical (IHC) and molecular expression and to determine the prognostic and predictive value of FGFR3 relative to BC.

PATIENTS AND METHODS: One hundred and sixty patients with diagnosed BC and 80 healthy controls were recruited. Urine samples were collected from all participants. DNA was extracted and FGFR3 mutations were examined in exons 7, 10, and 15 by polymerase chain reaction. IHC for FGFR3 expression and fluorescence in situ hybridization technique for assessment of gene amplification was also applied in tissue sections.

RESULTS: Ninety-eight (61.3%) patients were mutant in exon 7, 82 (51.3%) were mutant in exon 10, while only 14 (8.8%) were mutant in exon 15. Univariate logistic regression analysis revealed that mutations in the three exons of FGFR3 were statistically associated with BC and could be used as predictor and/or prognostic parameters for BC. Receiver operating characteristic analysis showed that the mutation of exons 7 and 10 could be used as diagnostic biomarkers for BC. Our findings confirm that FGFR3 mutations are associated with tumors of low grade and stage. The prevalence of mutations was significantly associated with recurrence and survival time of patients for all exons. Kaplan–Meier analysis revealed a significant association between mutant patients in exon 10 and survival time. Our findings suggest that estimation of FGFR3 expression and gene amplification could serve as a prognostic indicator in the follow-up of BC patients. It could also be utilized for molecular targeted therapy in BC.

CONCLUSION: Our data confirmed the feasibility of FGFR3 mutation detection in urine sediment. FGFR3 genetic mutations are independent prognostic factors for tumor recurrence and the genetic alternation of FGFR3 could be used for prediction of survival time of BC patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Li ZJ, Wang DY, Liu ZH. Clinical efficacy and quality of life assessment of partial cystectomy and plasmakinetic transurethral resection of tumor in bladder cancer patients. Cancer Manag Res. 2022;14:389-98. https://doi.org/10.2147/ CMAR.S346764 PMid:35115835 DOI: https://doi.org/10.2147/CMAR.S346764

World Health Organization/IARC. “Egypt Source: Globocan 2020. Vol. 895. Geneva: World Health Organization; 2020. p. 1-2.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7-33. https://doi.org/10.3322/caac.21708 PMid:35020204 DOI: https://doi.org/10.3322/caac.21708

Zhu CZ, Ting HN, Ng KH, Ong TA. A review on the accuracy of bladder cancer detection methods. J Cancer. 2019;10(17):4038-44. https://doi.org/10.7150/jca.28989 PMid:31417648 DOI: https://doi.org/10.7150/jca.28989

Roperch JP, Hennion C. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients-design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC). BMC Med Genet. 2020;21(1):112. https://doi.org/10.1186/ s12881-020-01050-w PMid:32448160 DOI: https://doi.org/10.1186/s12881-020-01050-w

Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21(2):104-21. https://doi.org/10.1038/s41568-020-00313-1 PMid:33268841 DOI: https://doi.org/10.1038/s41568-020-00313-1

Kacew A, Sweis RF. FGFR3 alterations in the era immunotherapy for urothelial bladder cancer. Front Immunol. 2020;11:575258. https://doi.org/10.3389/fimmu.2020.575258 PMid:33224141 DOI: https://doi.org/10.3389/fimmu.2020.575258

Ahmad F, Mahal V, Verma G, Bhatia S, Das BR. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients. Cancer Rep. 2018;1(3):e1130. https://doi.org/10.1002/cnr2.1130 DOI: https://doi.org/10.1002/cnr2.1130

Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003;63(23):8108-12 PMid:14678961

Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213(1):91-8. https://doi.org/10.1002/path.2207 PMid:17668422 DOI: https://doi.org/10.1002/path.2207

Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, et al. FGF3/FGF4 amplification and multiple lung metastases in responders to Sorafenib in hepatocellular carcinoma. Hepatology. 2013;57(4):1407-15. https://doi.org/10.1002/hep.25956 PMid:22890726 DOI: https://doi.org/10.1002/hep.25956

Ferro M, La Civita E, Liotti A, Cennamo M, Tortora F, Buonerba C, et al. Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer. J Pers Med. 2021;11(3):237. https://doi.org/10.3390/jpm11030237 PMid:33806972 DOI: https://doi.org/10.3390/jpm11030237

Wirtz RM, Frank F, Elke V, Kilic E, Watts R, Kellner R, et al. Association of FGFR alterations with FGFR 1-4 gene expression in TUR biopsies and matched NMP22 urine levels in early bladder cancer of the prospective real world clinico-pathological register trial: BRIDGister. J. Clin. Oncol., 2021;39. Philadelphia: Lippincott Williams & Wilkins. DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.e16533

Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013;12(7):1245-54. https://doi.org/10.1158/1535-7163.MCT-12-1150 PMid:23657946 DOI: https://doi.org/10.1158/1535-7163.MCT-12-1150

Junker K, van Oers GM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008;10(1):1-7. https://doi.org/10.1593/neo.07178 PMid:18231634 DOI: https://doi.org/10.1593/neo.07178

Salim EI, Morimura K, Menesi A, El-Lity M, Fukushima S, Wanibuchi H. Elevated oxidative stress and DNA damage and repair levels in urinary bladder carcinomas associated with schistosomiasis. Int J Cancer. 2008;123(3):601-8. https://doi.org/10.1002/ijc.23547 Mid:18478569 DOI: https://doi.org/10.1002/ijc.23547

Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, et al. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. J Clin Pathol. 2015;68(10):819-24. https://doi.org/10.1136/jclinpath-2015-202898 PMid:26251520 DOI: https://doi.org/10.1136/jclinpath-2015-202898

Hammam O, Aboushousha T, El-Hindawi A, Khairy H, Khalil H, Kamel A, et al. Expression of FGFR3 protein and gene amplification in urinary bladder lesions in relation to schistosomiasis. Open Access Maced J Med Sci. 2017;5(2):160-6. https://doi.org/10.3889/oamjms.2017.048 PMid:28507621 DOI: https://doi.org/10.3889/oamjms.2017.048

Fischbach A, Rogler A, Erber R, Stoehr R, Poulsom R, Heidenreich A, et al. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology. 2015;66(5):639-49. https://doi.org/10.1111/his.12473 PMid:24898159 DOI: https://doi.org/10.1111/his.12473

Khaled H. Schistosomiasis and cancer in Egypt: Review. J Adv Res. 2013;4(5):461-6. https://doi.org/10.1016/j.jare.2013.06.007 PMid:25685453 DOI: https://doi.org/10.1016/j.jare.2013.06.007

Miyake M, Sugano K, Kawashima K, Ichikawa H, Hirabayashi K, Kodama T, et al. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. Biochem Biophys Res Commun. 2007;362(4):865-71. https://doi.org/10.1016/j.bbrc.2007.08.092 PMid:17803960 DOI: https://doi.org/10.1016/j.bbrc.2007.08.092

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, et al. Tumor heterogeneity of fibroblast growth factor receptor3 (FGFR3) mutations in invasive bladder cancer: Implications for perioperative anti-FGFR3 treatment. Ann Oncol. 2018;27(7):1311-6. https://doi.org/10.1093/annonc/mdw170 PMid:27091807 DOI: https://doi.org/10.1093/annonc/mdw170

Al-Obaidy KI, Cheng L. Fibroblast growth factor receptor (FGFR) gene: Pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021;74(8):491-5. https://doi.org/10.1136/jclinpath-2020-207115 PMid:33731335 DOI: https://doi.org/10.1136/jclinpath-2020-207115

Van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, Jöbsis AC, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;64(6):1911-4. https://doi.org/10.1158/0008-5472.can-03-2421 PMid:15026322 DOI: https://doi.org/10.1158/0008-5472.CAN-03-2421

Nagata M, Muto S, Horie S. Molecular biomarkers in bladder cancer: Novel potential indicators of prognosis and treatment outcomes. Dis Markers. 2016;2016:8205836. https://doi.org/10.1155/2016/8205836 PMid:26924873 DOI: https://doi.org/10.1155/2016/8205836

Noel N, Couteau J, Maillet G, Gobet F, D’Aloisio F, Minier C, et al. TP53 and FGFR3 gene mutation assessment in urine: Pilot study for bladder cancer diagnosis. Anticancer Res. 2015;35(9):4915-21 PMid:26254388

Dodurga Y, Tataroglu C, Kesen Z, Satiroglu-Tufan NL. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res. 2011;10(1):86-95. https://doi.org/10.4238/vol10-1gmr923 PMid:21264819 DOI: https://doi.org/10.4238/vol10-1gmr923

Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664-71. https://doi.org/10.1200/JCO.2005.05.1771 PMid:16877735 DOI: https://doi.org/10.1200/JCO.2005.05.1771

Van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61(4):1265-8. PMid:11245416

Van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012;187(1):310-4. https://doi.org/10.1016/j.juro.2011.09.008 PMid:22099989 DOI: https://doi.org/10.1016/j.juro.2011.09.008

Kang HW, Kim YH, Jeong P, Park C, Kim WT, Ryu DH, et al.

Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncol Lett. 2017;14(3):3817-24. https://doi.org/10.3892/ol.2017.6621 PMid:28927152 DOI: https://doi.org/10.3892/ol.2017.6621

Van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650-7. https://doi.org/10.1016/j.eururo.2008.06.013 PMid:18584939 DOI: https://doi.org/10.1016/j.eururo.2008.06.013

Mayr R, Eckstein M, Wirtz RM, Santiago-Walker A, Baig M, Sundaram R, et al. Prognostic and predictive value of fibroblast growth factor receptor alterations in high-grade non-muscle- invasive bladder cancer treated with and without Bacillus Calmette-Guérin immunotherapy. Eur Urol. 2022;81(6):606-14. https://doi.org/10.1016/j.eururo.2022.02.028 PMid:35351346 DOI: https://doi.org/10.1016/j.eururo.2022.02.028

Van Rhijn BW, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: Implications for anti-FGFR3 treatment? Eur Urol. 2020;78(5):682-7. https://doi.org/10.1016/j.eururo.2020.07.002 PMid:32682615 DOI: https://doi.org/10.1016/j.eururo.2020.07.002

Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, Jaradat S, Al-Ghazo MA, et al. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 2010;34(6):724-32. https://doi.org/10.1016/j.canep.2010.05.003 PMid:20542753 DOI: https://doi.org/10.1016/j.canep.2010.05.003